Exelixis clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 2 with minor changes only.

1. Notable

   STELLAR-316 · Zanzalintinib Alone or in Combination With…STELLAR-316 · Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa · Colorectal Cancer With Molecular Residual Disease

   Recruitment opened

   Also in this update: Trial sites expanded: 0 → 13 locations

   Exelixis·Phase 3· NCT07750158· Registry history of NCT07750158 on ClinicalTrials.gov (opens the registry)

   Sep 21, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.